Chimeric Antigen Receptor Therapy.
作者信息
June Carl H, Sadelain Michel
机构信息
From the Center for Cellular Immunotherapies, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (C.H.J.); and the Center for Cell Engineering, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York (M.S.).
出版信息
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
Abstract
摘要
相似文献
1
Chimeric Antigen Receptor Therapy.
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
2
Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Anticancer Res. 2012 Jun;32(6):2377-83.
3
CAR therapy: the CD19 paradigm.
J Clin Invest. 2015 Sep;125(9):3392-400. doi: 10.1172/JCI80010. Epub 2015 Sep 1.
4
What CAR Will Win the CD19 Race?
Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070.
5
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Biosci Rep. 2017 Jan 27;37(1). doi: 10.1042/BSR20160332. Print 2017 Feb 28.
6
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
Mol Pharm. 2019 Aug 5;16(8):3544-3558. doi: 10.1021/acs.molpharmaceut.9b00418. Epub 2019 Jul 15.
7
CART trials are going ahead.
Sci China Life Sci. 2017 Nov;60(11):1276-1279. doi: 10.1007/s11427-017-9198-1. Epub 2017 Oct 26.
8
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
9
CARTs for Solid Tumors: Feasible or Infeasible?
Oncol Res Treat. 2017;40(9):540-546. doi: 10.1159/000477095. Epub 2017 Aug 17.
10
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24.
引用本文的文献
1
Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.
MedComm (2020). 2025 Sep 1;6(9):e70327. doi: 10.1002/mco2.70327. eCollection 2025 Sep.
2
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.
Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9.
3
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.
Front Immunol. 2025 Aug 15;16:1601385. doi: 10.3389/fimmu.2025.1601385. eCollection 2025.
4
CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases.
Front Immunol. 2025 Aug 13;16:1625166. doi: 10.3389/fimmu.2025.1625166. eCollection 2025.
5
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.
Front Immunol. 2025 Aug 12;16:1613878. doi: 10.3389/fimmu.2025.1613878. eCollection 2025.
6
Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.
Biomedicines. 2025 Aug 12;13(8):1963. doi: 10.3390/biomedicines13081963.
7
Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production.
Biomolecules. 2025 Aug 14;15(8):1166. doi: 10.3390/biom15081166.
8
Molecular Insights into Tumor Immunogenicity.
Curr Issues Mol Biol. 2025 Aug 11;47(8):641. doi: 10.3390/cimb47080641.
9
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.
Blood Cancer J. 2025 Aug 26;15(1):144. doi: 10.1038/s41408-025-01338-1.
10
Conversion of natural cytokine receptors into orthogonal synthetic biosensors.
Nat Chem Biol. 2025 Aug 22. doi: 10.1038/s41589-025-01986-1.
本文引用的文献
1
CAR T cell immunotherapy for human cancer.
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
2
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.
3
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.
4
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
5
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
6
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
7
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
8
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.
9
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.
Cancer Cell. 2017 Oct 9;32(4):506-519.e5. doi: 10.1016/j.ccell.2017.09.004.
10
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.
Cell Rep. 2017 Sep 26;20(13):3025-3033. doi: 10.1016/j.celrep.2017.09.002.
Zotero 插件